Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03382899 · ClinicalTrials.gov registry record · Phase 2
Study of Pegilodecakin (LY3500518) With Pembrolizumab Compared to Pembrolizumab Alone First-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer
A Phase 2 study, sponsored by Eli Lilly and Company.
- Terminated
- Registry status
- Phase 2
- Development phase
- 101
- Enrollment target
NCT03382899 is a Phase 2 study that was terminated before completion, run by Eli Lilly and Company. The registered enrollment target is 101 participants.
The verdict
NCT03382899, a Phase 2 study, was terminated before completion, sponsored by Eli Lilly and Company.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 101 participants
- Enrollment target
Study Summary
To compare the efficacy of pegilodecakin in combination with pembrolizumab versus pembrolizumab alone in participants with metastatic non-small cell lung cancer as measured by objective response rate.
Interventions
- DRUG Pembrolizumab
- BIOLOGICAL Pegilodecakin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 101 participants |
| Start Date | 2018-03-19 |
| Est. Completion | 2020-03-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03382899
The ClinicalTrials.gov registry entry for NCT03382899 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 101 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT03382899 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03382899 about?
NCT03382899 is a clinical study titled "Study of Pegilodecakin (LY3500518) With Pembrolizumab Compared to Pembrolizumab Alone First-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer". To compare the efficacy of pegilodecakin in combination with pembrolizumab versus pembrolizumab alone in participants with metastatic non-small cell lung cancer as measured by objective response rate.
What is the current status of trial NCT03382899?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 101 participants. The study started on 2018-03-19. Estimated completion is 2020-03-05.
What interventions are being tested in trial NCT03382899?
The interventions under investigation include: Pembrolizumab (DRUG), Pegilodecakin (BIOLOGICAL).
Who is sponsoring clinical trial NCT03382899?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.